Dr. Kaliappanadar Nellaiappan has more than 25 years of experience in the development of new drugs and therapeutic agents. He has led various teams to develop more than 100 dosage formulations throughout his career and continues to head a product development group at CuriRx since 2012.

He has also been involved in developing novel drug delivery systems for both hydrophobic and hydrophilic molecules, including peptides, and polymer-based oral nanoparticles. He has seven approved patents, several patent applications pending, and more than 50 publications to his name.

Prior to joining CuriRx, Dr. Nellaiappan served as a senior scientist at Formatech, Inc., where he was involved in the strategic direction of formulation development and analytical method development for small molecules and biologics. Before Formatech, he worked at Mass Biologics, developing a vaccine for Shiga toxins.

Dr. Nellaiappan received his PhD from the University of Madras and received Royal Society bursary award from Oxford University. He did his post-doctoral work at UMass Boston and Boston University.

Dr. Bijay Misra brings to his role as Project Leader his expertise in formulation and analytical science and his more than 20 years of experience in pharmaceuticals and biotechnology. Over the course of his career, he has worked on the translation of drug candidates from discovery into development through studies of pharmaceutical materials science and drug delivery applications. Before joining CuriRx, Dr. Misra held positions of increasing responsibility in pharmaceutical research and development and cGMP manufacturing at Vertex, Alkermes, and Borregaard Synthesis.

Dr. Misra received his Ph.D. in physical-organic chemistry from the City University of New York and held a research fellow position in bioanalytical chemistry working on cancer research at the American Health Foundation in New York prior to joining the industry.